Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Splitomicin is a small molecule inhibitor of Sir2p histone deacetylase activity, displaying higher activity in vivo (minimal inhibitory concentration = 0.49 µM) than in vitro (IC50 = 60 µM).1,2,3 It less effectively inhibits yeast Hst1, a paralog of Sir2p.2 Splitomicin has diverse effects on mammalian cells.4,5,6
WARNING This product is not for human or veterinary use.
1. Identification of a small molecule inhibitor of Sir2p. Proc. Natl. Acad. Sci. USA 98(26), 15113-15118 (2001).
2. Identification of selective inhibitors of NAD+-
3. Inhibitors of Sir2: Evaluation of splitomicin analogues. J. Med. Chem. 47, 2635-2644 (2004).
4. SIRT1 inhibition alleviates gene silencing in Fragile X mental retardation syndrome. PLoS Genet. 4(3), (2008).
5. Splitomicin suppresses human platelet aggregation via inhibition of cyclic AMP phosphodiesterase and intracellular Ca++ release. Thromb. Res. 124, 199-207 (2009).
6. Reciprocal roles of SIRT1 and SKIP in the regulation of RAR activity: Implication in the retinoic acid-